CHA

CHA Biotech is a South Korea-based public biotechnology and healthcare company within the broader CHA Medical Group. The company develops cell and gene therapies, with core capabilities in stem cell and immune cell therapeutics, and also operates related businesses in CDMO, cell banking, genomics, and healthcare services. Its lead disclosed clinical programs include CBT101, an autologous NK cell therapy for solid tumors and recurrent glioblastoma, and CordSTEM-DD, an umbilical cord-derived mesenchymal stem cell therapy for chronic low back pain caused by disc degeneration. CHA Biotech also has earlier-stage regenerative medicine programs in premature ovarian insufficiency, stroke, Parkinson's disease, retinal disease, and cartilage repair, and has licensed retinal regenerative technology to Astellas. The company leverages a large affiliated hospital and fertility network to support translational research and clinical development, while expanding global manufacturing through Korea, the U.S., and Japan.